Bipartisan congressional lawmakers are seeking input from experts about how to best set up a regulatory framework for the therapeutic use of psychedelics such as psilocybin and MDMA.
Reps. Jack Bergman (R-MI) and Lous Correa (D-CA), founders of the Congressional Psychedelics Advancing Therapies (PATH) Caucus, released a request for information from the public last month.
The lawmakers said they’re seeking to better understand “how to implement programs and policies that address the range of complex issues with potential novel therapies that may use a psychedelic or entactogenic drug in medically supervised and interpersonally supportive settings.”
“To gain a more complete understanding of the issues associated with use of these substances, the PATH Caucus believes that taking an inclusive, intentional, and reasoned approach to gathering input from the public may engender valuable insights that can more accurately and comprehensively characterize how different modalities incorporate the use of these substances while also ensuring responsible, accountable, safe, and ethical use,” the request says.
Any member of the public with relevant information are invited to provide feedback to the caucus by November 5. The lawmakers specified their interest in hearing from people with experience receiving psychedelics-assisted therapy, people working in the “bio-psycho-social-spiritual behavioral health
Read full article on Marijuana Moment
